Search

We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment.

As both mechanistic and geospatial malaria modeling methods become more integrated into malaria policy decisions, there is increasing demand for strategies that combine these two methods. This paper introduces a novel archetypes-based methodology for generating high-resolution intervention impact maps based on mechanistic model simulations. An example configuration of the framework is described and explored.

Research to eliminate one of the world’s deadliest diseases – malaria – will be accelerated thanks to a USD $4.7 million grant from the Gates Foundation for scientists at The Kids Research Institute Australia and The University of Western Australia (UWA).

The Malaria Atlas Project (MAP) – which houses the world’s largest malaria database and is at the forefront of efforts to track and tackle the disease – has been awarded more than $16 million by the Bill & Melinda Gates Foundation.

Disruptions of malaria case management caused by the COVID-19 pandemic likely contributed to an extra 76,000 malaria deaths in sub-Saharan Africa, according to analysis by The Kids Research Institute Australia and Curtin University.

A world-leading research team built to tackle malaria has relocated from Oxford University to Western Australia to take advantage of the state’s growing big data talent pool.

A USD $3.25 million international grant will see researchers from The Kids Research Institute Australia and The University of Western Australia play a pivotal role in accelerating the development of next-generation malaria vaccines, helping protect children from one of the world's deadliest infectious diseases.

Although the incidence of malaria is increased in women in endemic areas after delivery compared to non-pregnant women, no studies have assessed the benefit of presumptive antimalarial treatment given postpartum.

When models are used to inform decision-making, both their strengths and limitations must be considered. Using malaria as an example, we explain how and why models are limited and offer guidance for ensuring a model is well-suited for its intended purpose.

Seasonal malaria chemoprevention (SMC) is recommended for disease control in settings with moderate to high Plasmodium falciparum transmission and currently depends on the administration of sulfadoxine-pyrimethamine plus amodiaquine.